

平成 24 26 年度 研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Matsumoto A, <u>Yatsunashi H</u> , Nagaoka S, <u>Suzuki Y</u> , Hosaka T, <u>Tsuge M</u> , Chayama K, <u>Kanda T</u> , Yokosuka O, <u>Nishiguchi S</u> , Saito M, Miyase S, <u>Kang JH</u> , <u>Shinkai N</u> , <u>Tanaka Y</u> , Umemura T, <u>Tanaka E</u>	Factors associated with the effect of interferon-sequential therapy in order to discontinue nucleos(t)ide analogue treatment in patients with chronic hepatitis B	Hepatol Res			in press
Kamijo N, Matsumoto A, Umemura T, Shibata S, Ichikawa Y, Kimura T, Komatsu M, <u>Tanaka E</u>	Mutations of Pre-core and BCP Before and After HBeAg Seroconversion	World J Gastroenterol	21(2)	541-548	2015
<u>Tanaka E</u> , Matsumoto A	Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B	Hepatol Res	44 (1)	1-8	2014
Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, Han KH, Matsuura K, <u>Tanaka Y</u> , <u>Kurosaki M</u> , Asahina Y, Izumi N, <u>Kang JH</u> , Hige S, Ide T, Yamamoto K, Sakaida I, Murawaki Y, Itoh Y, Tamori A, Orito E, Hiasa Y, Honda M, Kaneko S, Mita E, Suzuki K, Hino K, <u>Tanaka E</u> , Mochida S, Watanabe M, Eguchi Y, Masaki N, Murata K, Korenaga M, Mawatari Y, Ohashi J, Kawashima M, Tokunaga K, Mizokami M	New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia	PLoS One	9 (2)	e86449	2014
Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, <u>Tanaka E</u>	Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B	Hepatol Res	44 (10)	E172-180	2014

Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, <u>Tanaka E</u>	Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B	Hepatol Res	44 (10)	E45-53	2014
Ikeda K, Izumi N, <u>Tanaka E</u> , Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Kumada H	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B	Hepatol Res	43(6)	596-604	2013
Matsumoto A, <u>Tanaka E</u> , Morita S, Yoshizawa K, Umemura T, Joshita S	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection	J Gastroenterol	47(9)	1006-1013	2012
Matsumoto A, <u>Tanaka E</u> , <u>Suzuki Y</u> , Kobayashi M, <u>Tanaka Y</u> , <u>Shinkai N</u> , Hige S, <u>Yatsuhashi H</u> , Nagaoka S, Chayama K, <u>Tsuge M</u> , Yokosuka O, <u>Imazeki F</u> , <u>Nishiguchi S</u> , Saito M, Fujiwara K, Torii N, <u>Hiramatsu N</u> , Karino Y, Kumada H	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B	Hepatol Res	42(2)	139-149	2012
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, <u>Kang JH</u> , Suzuki K, <u>Kurosaki M</u> , Asahina Y, Mochida S, Watanabe M, <u>Tanaka E</u> , Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, <u>Tanaka Y</u> , Tokunaga K, Mizokami M	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean	PLoS One	7(6)	e39175	2012
Watanabe T, <u>Tanaka Y</u> .	Reactivation of hepatitis viruses following immunomodulation systemic chemotherapy.	Hepatol Res	43(2)	113-21	2013

Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, <u>Tanaka Y</u> , Chu CK.	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.	Bioorg Med Chem Lett	23(2)	503-6	2013
Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, Urabe Y, Mbarek H, Tokunaga K, <u>Tanaka Y</u> , Sugiyama M, Mizokami M, Muroyama R, Tateishi R, Omata M, Koike K, Tanikawa C, Kamatani N, Kubo M, Nakamura Y, Matsuda K.	Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.	PLoS One	7(9)	e44743.	2012
Zhou B, Wang Z, Yang J, Sun J, Li H, <u>Tanaka Y</u> , Mizokami M, Hou J	Novel evidence of HBV recombination in family cluster infections in western China	PLoS One	7(6)	e38241	2012
Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, <u>Tanaka Y</u> , Zhang X, Narimatsu H.	Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels.	Clin Chim Acta	413 (21-22)	1796-9	2012
Ragheb M, Elkady A, <u>Tanaka Y</u> , Murakami S, Attia FM, Hassan AA, Hassan MF, Shedid MM, Abdel Reheem HB, Khan A, Mizokami M.	Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt.	J Med Virol	84(4)	587-95.	2012
Posuwan N, Payungporn S, Tangkijvanich P, Ogawa S, Murakami S, Iijima S, Matsuura K, <u>Shinkai N</u> , Watanabe T, Poovorawan Y, Tanaka Y.	Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in Thai population.	PLoS One	9(1)	e86007	2014
<u>Shinkai N</u> , Matsuura K, Sugauchi F, Watanabe T, Murakami S, Iio E, Ogawa S, Nojiri S, Joh T, <u>Tanaka Y</u> .	Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance.	J Clin Microbiol	51 (11)	3484-3491.	2013

Yamada R, <u>Hiramatsu N</u> , Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; the Osaka Liver Forum.	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.	J Gastroenterol				In press
Nishida T, <u>Hiramatsu N</u> , Mizuki M, Nagatomo I, Kida H, Tazumi K, Shinzaki S, Miyazaki M, Yakushijin T, Tatsumi T, Iijima H, Kiso S, Kanto T, Tsujii M, Takehara T.	Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic.	HepatoI Res	43(4)	339-346	2013	
Nawa T, Ishida H, Tatsumi T, Li W, Shimizu S, Kodama T, Hikita H, Hosui A, Miyagi T, Kanto T, <u>Hiramatsu N</u> , Hayashi N, Takehara T.	Interferon-suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway.	Virology	5:432 (2)	452-9.	2012	
Hosaka T, Suzuki F, Kobayashi M, Fukushima T, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleo(s)ide analogue therapy.	Liver Int		Epub ahead of print	2014	
Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, <u>Suzuki Y</u> , Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol	49	538-546	2014	
Hara T, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Kumada H	Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients.	J Viral Hepat	21	802-808	2014	

Suzuki F, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, Kumada H	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.	Drug Des Devel	8	869-873	2014
Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.	J Gastroenterol	49	470-480	2014
Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.	J Gastroenterol	49	1094-1104	2014
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Correlation Between Hepatitis B Virus Surface Antigen Level and Alpha-Fetoprotein in Patients Free of Hepatocellular Carcinoma or Severe Hepatitis.	J Med Virol	86	131-138	2014
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection	Hepatology	58	98-107	2013
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	J Gastroenterol	48	930-941	2013
Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan	J Gastroenterol	47	814-822	2012

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.	Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients	J Hepatol	57	508-514	2012
Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki Y</u> , Arase Y, Ikeda K, Kobayashi M, Kumada H.	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection	J Gastroenterol	47	1022-1029	2012
Matsumoto N, Arase Y, Seko Y, Imai N, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Suzuki F, Ikeda K, Kumada H, Aida K, Kobayashi T.	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of < 126 mg/dl	Hepatol Res	42	558-563	2012
Bae SK, <u>Yatsushashi H</u> , Takahara I, Tamada Y, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Yanagi K, Abiru S, Komori A, Ishibashi H.	Sequential occurrence of acute hepatitis B among members of a high school Sumo wrestling club.	Hepatol Res	44 (10)	E267-272	2014
Ito K, Yotsuyanagi H, <u>Yatsushashi H</u> , Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59(1)	89-97	2014
Bae SK, <u>Yatsushashi H</u> , Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Abiru S, Komori A, Migita K, Nakamura M, Ito M, Miyakawa Y, Ishibashi H.	Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.	Med Sci Monit	18 (12)	CR 698-705	2012

Migita K, Abiru S, Ohtani M, Jiuchi Y, Maeda Y, Bae SK, Bekki S, Hashimoto S, Yesmembetov K, Nagaoka S, Nakamura M, Komori A, Ichikawa T, Nakao K, <u>Yatsuhashi H</u> , Ishibashi H, Yasunami M.	HLA-DP gene polymorphisms and hepatitis B infection in the Japanese population.	Transl Res	160 (6)	443-444	2012
Toyama T, Ishida H, Ishibashi H, <u>Yatsuhashi H</u> , Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E.	Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.	Hepatol Res	42 (12)	1168-1174	2012
Tamada Y, <u>Yatsuhashi H</u> , Masaki N, Nakamuta M, Mita E, Komatsu T, Watanabe Y, Muro T, Shimada M, Hijioka T, Satoh T, Mano Y, Komeda T, Takahashi M, Kohno H, Ota H, Hayashi S, Miyakawa Y, Abiru S, Ishibashi H.	Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.	Gut	61(5)	765-773	2012
Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K, Hashimoto K, Ishii A, Takashima T, Iwata K, Saito M, Imanishi H, Iijima H, <u>Nishiguchi S</u> .	An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients.	Gastroenterol Res Pract			2014
Enomoto M, <u>Nishiguchi S</u> , Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H, Kawada N.	Entecavir and interferon- α sequential therapy in Japanese patients with hepatitis B e antigen- positive chronic hepatitis B	J Gastroenterol	48	397-404	2013
Enomoto M, Tamori A, <u>Nishiguchi S</u> , Kawada N.	Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential	J Gastroenterol	48	999-1005	2013

Tani Y, Aso H, Matsukura H, Tadokoro K, Tamori A, <u>Nishiguchi S</u> , Yoshizawa H, Shibata H.	Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections	Vox Sanguinis	102	285-293	2012
Akamatsu S, Hayes CN, <u>Tsuge M</u> , Miki D, Akiyama R, Ochi H, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama PK.	Differences in serum microRNA profiles in hepatitis B and C virus infection.	J Infect			in press
Huang YW, Takahashi S, <u>Tsuge M</u> , Chen CL, Wang TC, Abe H, Hu JT, Chen DS, Yang SS, Chayama K. and Kao JH.	On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.	Antivir Ther			in press
Kohno T, <u>Tsuge M</u> , Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, Hayes C.N. and Chayama K.	Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.	J Viral Hepat	21(9)	e89-97	2014
<u>Tsuge M.</u> and Chayama K.	Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy.	J Gastroenterol	48(6)	779-80	2013
Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, <u>Tsuge M</u> , Abe H, Hayes C.N, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T. and Chayama K.	A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.	Biochem Biophys Res Commun	441 (1)	230-5	2013

Arataki K, Hayes C.N, Akamatsu S, Akiyama R, Abe H, <u>Tsuge M</u> , Miki D, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami H, Ohishi W. and Chayama K.	Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B.	J Med Virol	85(5)	789-98	2013
<u>Tsuge M</u> , Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H. and Chayama K.	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.	J Gastroenterol	48 (10)	1188-204	2013
Hayes CN, Akamatsu S, <u>Tsuge M</u> , Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, Chayama K.	Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle.	PLoS One	7(10)	e47490	2012
Nakamura M, <u>Kanda T</u> , Nakamoto S, Haga Y, Sasaki R, Jiang X, Yasui S, Arai M, Yokosuka O.	Reappearance of serum HBV DNA in patients with hepatitis B surface antigen seroclearance.	Hepatology		[Epub ahead of print]	2015
Yasui S, Fujiwara K, Nakamura M, Miyamura T, Yonemitsu Y, Mikata R, Arai M, <u>Kanda T</u> , Imazeki F, Oda S, Yokosuka O.	Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B.	J Viral Hepat	22(2)	94-102	2015
Sarkar N, Panigrahi R, Pal A, Biswas A, Singh SP, Kar SK, Bandopadhyay M, Das D, Saha D, <u>Kanda T</u> , Sugiyama M, Chakrabarti S, Banerjee A, Chakravarty R.	Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP- in hepatocytes.	J Viral Hepat		[Epub ahead of print]	2015
Nakamoto S, <u>Kanda T</u> , Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Takeda Y, Mimura N, Iseki T, Wu S, Arai M, Imazeki F, Saito K, Shirasawa H, Yokosuka O.	Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.	Int J Mol Sci	15 (11)	21455-67	2014

Jiang X, <u>Kanda T</u> , Wu S, Nakamura M, Miyamura T, Nakamoto S, Banerjee A, Yokosuka O.	Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.	World J Gastroenterol	20 (23)	7197-206	2014
Jiang X, <u>Kanda T</u> , Tanaka T, Wu S, Nakamoto S, Imazeki F, Yokosuka O.	Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines.	Immunol Lett	152 (1)	8-15	2013
Miyauchi T, <u>Kanda T</u> , Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Kato K, Arai M, Mikami S, Sugiura N, Kimura M, Goto N, Imazeki F, Yokosuka O.	Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.	Int J Med Sci	10(6)	647-52	2013
Kamezaki H, <u>Kanda T</u> , Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F, Nomura F, Yokosuka O.	Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine.	Int J Med Sci	10(5)	567-74	2013
Wu S, <u>Kanda T</u> , Imazeki F, Nakamoto S, Tanaka T, Arai M, Roger T, Shirasawa H, Nomura F, Yokosuka O.	Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.	J Infect Dis	206 (3)	415-20	2012
Matsui T, <u>Kang JH</u> , Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai H, Maemori M, Maguchi H, Tanaka Y.	Reactivation of hepatitis B virus in Patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma	J Med Virol	85 (11)	1900-6.	2013

Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, <u>Kang JH</u> , Abe K, Mochida S, Watanabe M, <u>Kurosaki M</u> , Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, Hiasa Y, Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations	BMC Med Genet	13:47	doi: 10.1186/1471-2350-13-47	2012
Orito E, Hasebe C, <u>Kurosaki M</u> , Osaki Y, Jyoko K, Watanabe H, Kimura H, Nishijima N, Kusakabe A, Izumi N.	Risk of hepatocellular carcinoma in cirrhotic HBV patients during nucleot(s)ide analogues therapy.	Hepatol Res			in press
Ito K, Yotsuyanagi H, <u>Yatsunami H</u> , Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, <u>Kurosaki M</u> , Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59	89-97	2014
<u>Kurosaki M</u> , Tsuchiya K, Nakanishi H, Itakura J, Izumi N.	Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy	Journal of Gastroenterology	48	777-778	2013
Shibayama M, Serrano-Luna J, Sohda T, Kawashima M, Yamauchi E, Tanaka T, Ueda SI, Morihara D, Anan A, Takeyama Y, Irie M, Iwata K, Shakado S, <u>Sakisaka S</u>	Restoration of albumin production by nucleoside analogue therapy in patients with chronic hepatitis B.	Med Mol Morphol	47(4)	207-212	2014